



Swift Biosciences, Inc.
58 Parkland Plaza, Suite 100
Ann Arbor, MI 48103

Steve Spotts Joins Swift Biosciences as Chief Commercial Officer

Ann Arbor, MI – March 10, 2011 - Swift Biosciences Inc., a developer of innovative genetic analysis tools for the research and diagnostic industries, today announced that Steve Spotts has joined the company as Chief Commercial Officer.

Swift Biosciences recently announced their myT™ Primer qPCR technology that can detect cancer mutations with very high sensitivity and specificity. To date myT Assays have been developed for two cancer genes, KRAS and BRAF, and additional assays are in progress. The myT Assays are expected to be useful for both research and clinical diagnostics.

“We feel fortunate to have Steve join our team,” said David Olson, PhD and CEO at Swift Biosciences. Dr. Olson added “We are enthusiastic about the response to our product prototypes and look forward to commercializing products in the near future with Steve’s help.”

“I am very excited about the technologies Swift has and continues to develop,” said Steve Spotts. “We are well positioned to provide the innovations that are being sought after in both the research and clinical diagnostic markets.”

About myT™ Primer qPCR technology

Swift Biosciences has developed myT™ Primers, which enable highly selective qPCR assays for detection of cancer mutations. myT Assays are based on proprietary primers that have unique thermodynamic properties that make them highly sensitive to mismatch discrimination. A gating factor in the performance of allele-specific qPCR lies with the “detection” primer (the primer which hybridizes to DNA at the mutation site). Detection primers must stringently discriminate between mutant and normal sequences to achieve high analytical sensitivity (minimum copy number of mutant DNA that generates a detectable signal) and high analytical specificity (maximum copy number of wild type DNA that does not result in a detectable signal). The distinctive physical characteristics of myT Primers enable both high sensitivity and specificity, making them ideal for cancer research and diagnostic research applications. To date, allele-specific assays have been developed for the common mutations in the KRAS and BRAF genes. myT Primers work in conventional qPCR machines using standard single tube format.

About Swift Biosciences

Swift Biosciences Inc., based in Ann Arbor, MI, is an innovative developer molecular biology protocols and reagents for research and diagnostic research applications. The Company’s novel platform technologies are being developed for qPCR and Next Generation Sequencing markets.

Swift Biosciences' products are designed to produce better and faster results, at lower cost and be compatible with customers' existing systems.

For more information about Swift Biosciences please visit www.SwiftBioSci.com

Company Contact:

David Olson, PhD

President and CEO

58 Parkland Plaza, Suite 100

Ann Arbor, MI 48103

info@swiftbiosci.com

